OnCo
cancersCancer

Hodgkin lymphoma

Hodgkin lymphoma is one of the most curable cancers, where the goal is now to cure with less toxicity, using brentuximab and, from 2026, first-line nivolumab.

Classical Hodgkin lymphoma is a B-cell cancer in which rare, giant Reed-Sternberg cells (about 1% of the mass) recruit an inflammatory microenvironment and hide behind amplified PD-L1. It peaks in young adults and again after 55, is staged with PET-CT and the Lugano system, and is cured in more than 85% of patients overall and in over 90% of early-stage disease. Because most patients are young and will live for decades, the field's defining problem is not cure but the cost of cure: anthracycline heart disease, bleomycin lung injury, infertility, and second cancers from alkylators and radiation.

That is why Hodgkin lymphoma pioneered response-adapted therapy. Interim PET after two cycles (Deauville score) steers de-escalation (drop bleomycin after negative PET2 in RATHL; omit radiotherapy in early stage in HD16/HD17/RAPID at a small PFS cost) or escalation to BEACOPP-type regimens. Two ADC- and immunotherapy-based regimens then replaced ABVD for advanced disease: brentuximab vedotin-AVD (ECHELON-1, overall survival benefit) and, from March 2026, nivolumab-AVD (SWOG S1826, PFS HR 0.45 versus BV-AVD, neuropathy halved, children and adults together). In Europe, GHSG HD21's PET-guided BrECADD matches escalated BEACOPP's ~94% PFS with far less toxicity. Relapse is treated with PD-1 blockade (pembrolizumab beat brentuximab in KEYNOTE-204), brentuximab, salvage chemotherapy and autologous transplant, with brentuximab consolidation for high-risk patients (AETHERA); allogeneic transplant and CD30 CAR-T are options for the few who fail everything.

The next questions are how far chemotherapy can be removed. AHOD2131 tests brentuximab-nivolumab in early-stage disease across children and adults; ctDNA may replace PET for steering; older patients, who have half the cure rate of young ones, need regimens they can tolerate (nivolumab-AVD, brentuximab-based). Survivorship care for the tens of thousands cured decades ago, and the shift from radiotherapy to systemic de-escalation, remain the field's distinctive concerns.

State of the art today

  • Immunotherapy in first line with less toxicity.
  • Interim PET steers therapy for nearly every patient: bleomycin omission (RATHL), radiotherapy omission (HD16/17, RAPID), cycle number (HD18, HD21).
  • Radiotherapy is disappearing from advanced-stage care (<1% in S1826) and being minimised in early stage.
  • PD-1 blockade is the most effective single agent in any lymphoma relapse (ORR ~70%), and beat brentuximab head to head (KEYNOTE-204).
  • Cure rates above 90% in young patients shift the research agenda to late effects and to older adults.
Show survival figures (2)

Averages across everyone diagnosed, often years ago. Your stage, subtype, age, fitness and the treatment you receive matter more than the average, and the numbers are improving quickly.

  • Nivolumab-AVD is the new frontline standard for advanced disease (S1826: 2-year PFS 92%, neuropathy halved), approved March 2026 for ages 12 and up.
  • Two intensive but de-toxified European options: PET-guided BrECADD (HD21) achieves ~94% 5-year PFS with 40% less morbidity than eBEACOPP.
Who it affects
Show survival figures (1)

Averages across everyone diagnosed, often years ago. Your stage, subtype, age, fitness and the treatment you receive matter more than the average, and the numbers are improving quickly.

  • ~83,000 new cases and ~23,000 deaths a year worldwide; ~8,500 US cases; bimodal age peaks (20-30 and >55); five-year survival ~89% overall in high-income countries.

Where the cases are

Cases by country · GLOBOCAN 2022
All countries →

Site: Hodgkin lymphoma. World: 82,469 new cases, 22,733 deaths.

#CountryNew casesDeaths
1India9,6113,522
2United States of America8,536929
3China4,3631,931
4Russian Federation3,015774
5Brazil2,667640
6Germany2,419330
7Mexico2,341659
8United Kingdom2,270310
9Italy2,190425
10Nigeria1,989920

Standard of care

9top
Advanced stage

Nivolumab-AVD (2026) or BV-AVD; PET-adapted.

NCCN Guidelines: Hodgkin Lymphoma
NivolumabBrentuximab vedotinFDG PET
Early stage, favourable (I-II)

ABVD × 2 + involved-site radiotherapy 20 Gy (HD10), or PET-adapted omission of radiotherapy after 3 cycles if PET-negative (RAPID, HD16) accepting ~5% lower PFS; AHOD2131 tests BV-nivo.

NCCN · Category 1 (ABVD × 2 + ISRT 20 Gy or PET-ad…
DoxorubicinPET-adapted (response-adapted) therapyIMRT / IGRT (modern external beam)Deauville five-point scaleAHOD2131 (COG / NCTN)
Early stage, unfavourable (I-II bulky or risk factors)

ABVD × 4 + ISRT 30 Gy, or escalated BEACOPP × 2 + ABVD × 2 + RT (HD14/HD17 PET-guided); nivolumab- or BV-containing regimens in trials.

NCCN · Category 2A
DoxorubicinPET-adapted (response-adapted) therapyIMRT / IGRT (modern external beam)
Advanced stage (III-IV), age ≤60

Nivolumab-AVD × 6 (S1826; approved March 2026, no routine radiotherapy) or BV-AVD × 6 with G-CSF (ECHELON-1); in Europe PET-guided BrECADD × 4-6 (HD21) or eBEACOPP; PET-adapted ABVD/AVD (RATHL) where novel agents unavailable.

NCCN · Category 1 (nivolumab-AVD preferred; BV-AVD)ESMO-MCBS · A (ECHELON-1)
SWOG S1826NivolumabECHELON-1Brentuximab vedotinGHSG HD21RATHLPD-1 blockade + AVD chemotherapy
Advanced stage, age >60

Nivolumab-AVD (S1826 included older adults with less toxicity than BV-AVD); sequential brentuximab → AVD → brentuximab; avoid bleomycin; ABVD/AVD with dose adaptation.

SWOG S1826NivolumabBrentuximab vedotinCaution: bleomycin lung toxicity, especially with brentuximab or G-CSF
First relapse, transplant-eligible

Salvage (ICE, DHAP, GVD, BV-nivolumab or pembrolizumab-GVD) → PET-negative → high-dose therapy and autologous transplant; brentuximab consolidation for high-risk (AETHERA); PD-1 maintenance in trials.

NCCN · Category 1 (ASCT after chemosensitive salva…
Autologous stem cell transplant (high-dose therapy)Brentuximab vedotinNivolumabPembrolizumabAETHERA
Relapse after transplant or transplant-ineligible

Pembrolizumab (KEYNOTE-204) or nivolumab; brentuximab vedotin if not yet given; BV + nivolumab; allogeneic transplant for fit patients after response; CD30 CAR-T in trials; palliative radiotherapy or bendamustine.

NCCN · Category 1 (pembrolizumab, nivolumab, brent…
PembrolizumabKEYNOTE-204NivolumabCheckMate 205Brentuximab vedotinCD30 CAR-T for multiply relapsed Hodgkin lymphoma
Paediatric (COG / EuroNet)

Risk-adapted OEPA/COPDAC (EuroNet-PHL-C2) or ABVE-PC with brentuximab (AHOD1331, EFS benefit) and PET-guided radiotherapy omission; S1826 and AHOD2131 now enrol from age 12 or 5.

Brentuximab vedotinPET-adapted (response-adapted) therapyChildren's Oncology Group (COG)
Survivorship

Lifelong surveillance for cardiac disease (anthracycline, mediastinal RT), breast cancer screening from 8 years after chest RT in women, thyroid and lung checks, fertility counselling before therapy.

Cardio-oncologyMammography & tomosynthesis

Subtypes & biomarkers

top
Subtypes
Biomarkers clinicians test

Target prevalence in this cancer

History

19top
  1. 1832Thomas Hodgkin describes the disease; Reed and Sternberg characterise the cell (1898-1902)
    Reed-Sternberg cell
  2. 1950Peters shows extended-field radiotherapy can cure early-stage disease
    IMRT / IGRT (modern external beam)
  3. 1964MOPP: first combination chemotherapy cure
  4. 1964MOPP: the first combination chemotherapy to cure an advanced cancer (DeVita, NCI)
    Cytotoxic chemotherapy
  5. 1975ABVD introduced (Bonadonna); becomes global standard by the 1990s
    Doxorubicin
  6. 1992Escalated BEACOPP developed by the German Hodgkin Study Group
    German Breast Group (GBG)
  7. 2000Autologous transplant standard for relapse; late-effects registries reveal cardiac and second-cancer burden
    Autologous stem cell transplant (high-dose therapy)Cardio-oncology
  8. 2011Brentuximab vedotin approved
    Brentuximab vedotin
  9. 2011Brentuximab vedotin approved for relapsed disease; CD30 validated as an ADC target
    Brentuximab vedotinCD30
  10. 2014Lugano classification formalises PET staging and the Deauville scale
    Lugano classification / Ann Arbor stagingDeauville five-point scale
  11. 2015AETHERA: brentuximab consolidation after transplant
    AETHERA
  12. 2016RATHL: bleomycin dropped after negative interim PET; nivolumab approved for relapse (CheckMate 205)
    RATHLCheckMate 205Nivolumab
  13. 2018ECHELON-1: BV-AVD approved frontline; radiotherapy omission trials (RAPID, HD16/17) report
    ECHELON-1PET-adapted (response-adapted) therapy
  14. 2020KEYNOTE-204: pembrolizumab beats brentuximab in relapse
    KEYNOTE-204Pembrolizumab
  15. 2022ECHELON-1 shows overall survival benefit; WHO reclassifies nodular lymphocyte-predominant disease
    ECHELON-1
  16. 2023SWOG S1826: nivolumab-AVD beats BV-AVD (ASCO plenary)
    SWOG S1826
  17. 2024HD21 (BrECADD) published in Lancet; S1826 in NEJM
    GHSG HD21SWOG S1826
  18. 2026Nivolumab-AVD approved first line
    Nivolumab
  19. 2026Nivolumab-AVD approved by FDA (20 March) for ages 12+; HD21 5-year data confirm BrECADD
    SWOG S1826NivolumabGHSG HD21

Pipeline

7top

Open problems

  • Late toxicity in survivors.
  • Older patients.
  • Late effects dominate: cardiac disease, breast and lung cancer after mediastinal radiotherapy, infertility; survivors need lifelong surveillance that most health systems do not organise.
  • Older patients (>60) have roughly half the cure rate and double the toxicity; the best regimen for them is unsettled.
  • The ~10-15% with primary refractory or early-relapsing disease still need transplant; those failing PD-1 blockade have few options beyond allogeneic transplant.
  • Interim PET has limited positive predictive value; ctDNA-guided designs are unproven.
  • Access: brentuximab and nivolumab are costly and unavailable in many countries where EBV-positive Hodgkin lymphoma is common in children.
  • Nodular lymphocyte-predominant disease is now a separate entity with little trial evidence of its own.
  • Radiotherapy omission trades a few percent of PFS for lower late toxicity; the right trade-off differs by age and sex.

Trials

top

Recruiting now (live from ClinicalTrials.gov)

Recruiting trials near you · live from ClinicalTrials.gov
Hodgkin lymphoma
condition: Hodgkin lymphoma
Open on ClinicalTrials.gov →

Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.

Landmark trials in OnCo

AETHERAAHOD2131 (COG / NCTN)CheckMate 205ECHELON-1GHSG HD21KEYNOTE-204RATHLSWOG S1826

Expert centres

top
Where the expertise is

Centres linked to this cancer in OnCo

Seeking a second opinion: ask your oncologist for a referral to a high-volume centre; most accept records and pathology by mail or telehealth. In the US, use the NCI's Find a Cancer Center tool or the nonprofit Cancer Commons, which navigates options for advanced cancers at no cost.

Questions to ask

top
Bring to your appointment

Questions to ask your oncologist about Hodgkin lymphoma

Generated from this cancer's standard of care, biomarkers, and pipeline · 31 questions

Newly diagnosed

  1. What is my exact diagnosis, stage, and grade, and which tests established them?
    Why: Everything else follows from an accurate stage and subtype.
  2. Which biomarkers have been tested on my tumour (for example Interim PET, CD30, PD-L1, Interim PETafter cycle 2, CD30 and CD15 on Reed-Sternberg cells; CD20 in NLPBL), and what were the results?
    Why: These results decide eligibility for targeted therapy, immunotherapy, and trials.
  3. Which subtype is my cancer, and does that change the recommended treatment?
    Why: Recognised subtypes for this cancer include Classical Hodgkin lymphoma: nodular sclerosis, mixed cellularity, lymphocyte-rich, lymphocyte-depleted, Nodular lymphocyte-predominant B-cell lymphoma, Early stagefavourable vs unfavourable.
  4. Is germline (inherited) genetic testing recommended for me or my family?
    Why: Inherited variants can change treatment and matter for relatives.

Advanced stage

  1. For my situation (advanced stage), which of the standard options do you recommend and why?
    Why: Guideline options include: Nivolumab-AVD (2026) or BV-AVD; PET-adapted.
  2. Am I a candidate for Nivolumab, Brentuximab vedotin, and what side effects should I expect?
    Why: Knowing the expected toxicities helps you plan work, family, and supportive care.

Early stage, favourable (I-II)

  1. For my situation (early stage, favourable (i-ii)), which of the standard options do you recommend and why?
    Why: Guideline options include: ABVD × 2 + involved-site radiotherapy 20 Gy (HD10), or PET-adapted omission of radiotherapy after 3 cycles if PET-negative (RAPID, HD16) accepting ~5% lower PFS; AHOD2131 tests BV-nivo.
  2. Am I a candidate for Doxorubicin, and what side effects should I expect?
    Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
  3. How do the results of AHOD2131 (COG / NCTN) apply to someone like me?
    Why: Trial populations differ from individual patients; ask how closely you match.

Early stage, unfavourable (I-II bulky or risk factors)

  1. For my situation (early stage, unfavourable (i-ii bulky or risk factors)), which of the standard options do you recommend and why?
    Why: Guideline options include: ABVD × 4 + ISRT 30 Gy, or escalated BEACOPP × 2 + ABVD × 2 + RT (HD14/HD17 PET-guided); nivolumab- or BV-containing regimens in trials.
  2. Am I a candidate for Doxorubicin, and what side effects should I expect?
    Why: Knowing the expected toxicities helps you plan work, family, and supportive care.

Advanced stage (III-IV), age ≤60

  1. For my situation (advanced stage (iii-iv), age ≤60), which of the standard options do you recommend and why?
    Why: Guideline options include: Nivolumab-AVD × 6 (S1826; approved March 2026, no routine radiotherapy) or BV-AVD × 6 with G-CSF (ECHELON-1); in Europe PET-guided BrECADD × 4-6 (HD21) or eBEACOPP; PET-adapted ABVD/AVD (RATHL) where novel agents unavailable.
  2. Am I a candidate for Nivolumab, Brentuximab vedotin, and what side effects should I expect?
    Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
  3. How do the results of SWOG S1826 and ECHELON-1 apply to someone like me?
    Why: Trial populations differ from individual patients; ask how closely you match.

Advanced stage, age >60

  1. For my situation (advanced stage, age >60), which of the standard options do you recommend and why?
    Why: Guideline options include: Nivolumab-AVD (S1826 included older adults with less toxicity than BV-AVD); sequential brentuximab → AVD → brentuximab; avoid bleomycin; ABVD/AVD with dose adaptation.
  2. Am I a candidate for Nivolumab, Brentuximab vedotin, and what side effects should I expect?
    Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
  3. How do the results of SWOG S1826 apply to someone like me?
    Why: Trial populations differ from individual patients; ask how closely you match.

First relapse, transplant-eligible

  1. For my situation (first relapse, transplant-eligible), which of the standard options do you recommend and why?
    Why: Guideline options include: Salvage (ICE, DHAP, GVD, BV-nivolumab or pembrolizumab-GVD) → PET-negative → high-dose therapy and autologous transplant; brentuximab consolidation for high-risk (AETHERA); PD-1 maintenance in trials.
  2. Am I a candidate for Brentuximab vedotin, Nivolumab, Pembrolizumab, and what side effects should I expect?
    Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
  3. How do the results of AETHERA apply to someone like me?
    Why: Trial populations differ from individual patients; ask how closely you match.

Relapse after transplant or transplant-ineligible

  1. For my situation (relapse after transplant or transplant-ineligible), which of the standard options do you recommend and why?
    Why: Guideline options include: Pembrolizumab (KEYNOTE-204) or nivolumab; brentuximab vedotin if not yet given; BV + nivolumab; allogeneic transplant for fit patients after response; CD30 CAR-T in trials; palliative radiotherapy or bendamustine.
  2. Am I a candidate for Pembrolizumab, Nivolumab, Brentuximab vedotin, and what side effects should I expect?
    Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
  3. How do the results of KEYNOTE-204 and CheckMate 205 apply to someone like me?
    Why: Trial populations differ from individual patients; ask how closely you match.

Paediatric (COG / EuroNet)

  1. For my situation (paediatric (cog / euronet)), which of the standard options do you recommend and why?
    Why: Guideline options include: Risk-adapted OEPA/COPDAC (EuroNet-PHL-C2) or ABVE-PC with brentuximab (AHOD1331, EFS benefit) and PET-guided radiotherapy omission; S1826 and AHOD2131 now enrol from age 12 or 5.
  2. Am I a candidate for Brentuximab vedotin, and what side effects should I expect?
    Why: Knowing the expected toxicities helps you plan work, family, and supportive care.

Survivorship

  1. For my situation (survivorship), which of the standard options do you recommend and why?
    Why: Guideline options include: Lifelong surveillance for cardiac disease (anthracycline, mediastinal RT), breast cancer screening from 8 years after chest RT in women, thyroid and lung checks, fertility counselling before therapy.

Any stage

  1. Are there clinical trials I could join, for example of AHOD2131 (COG / NCTN), Chemotherapy-free Hodgkin lymphoma: brentuximab + PD-1 in early stage, CD30 CAR-T for multiply relapsed Hodgkin lymphoma, ctDNA monitoring in lymphoma (PhasED-seq, clonoSEQ)?
    Why: Trials are how the next standard of care is set; asking early keeps options open.
  2. Would a second opinion at a high-volume centre change anything, and can you help arrange it?
    Why: Rare or high-stakes decisions benefit from a centre that treats many similar patients.
  3. What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?
    Why: Supportive care improves quality of life and helps patients complete treatment.
  4. I read that “Late toxicity in survivors”. How does that affect my plan?
    Why: Open problems are where trials and second opinions matter most.
  5. I read that “Older patients”. How does that affect my plan?
    Why: Open problems are where trials and second opinions matter most.

Print this page for your appointment (your browser's print command). These prompts are for discussion; your clinical team knows your case.

Everything relevant

95top

Direct links plus the targets, companies, and technologies of this cancer's products.

technologies

13
Antibody-drug conjugate (ADC)Autologous stem cell transplant (high-dose therapy)Cardio-oncologyctDNA monitoring in lymphoma (PhasED-seq, clonoSEQ)Cytotoxic chemotherapyElectrochemotherapyFDG PETImmune checkpoint inhibitorsIMRT / IGRT (modern external beam)Mammography & tomosynthesisOncofertility and fertility preservationPET-adapted (response-adapted) therapySurvivorship care and late-effects surveillance

targets

3
CD30PD-1PD-L1

drugs

8
Not mapped hereGlycopeptide antibiotic (DNA-cleaving)
Bleomycin · Blenoxane
ApprovedADC
Brentuximab vedotin · Adcetris
ApprovedCytotoxic chemotherapy (anthracycline)
Doxorubicin · Adriamycin
ApprovedMonoclonal antibody (anti-PD-1)
Nivolumab · Opdivo / Opdivo Qvantig (SC)
ApprovedMonoclonal antibody (anti-PD-1)
Pembrolizumab · Keytruda / Keytruda Qlex (SC)
Not mapped hereAnti-PD-1 monoclonal antibody (IgG1, Fc-engineered null)
Penpulimab · Penpulimab-kcqx
Not mapped hereVinca alkaloid (microtubule inhibitor)
Vinblastine · Velban
Not mapped hereVinca alkaloid (microtubule inhibitor)
Vincristine · Oncovin / Marqibo

companies

6
AkesoBristol Myers SquibbForesight DiagnosticsMerck & Co. (MSD)Pfizer (incl. Seagen)Takeda

institutions

19
American Society of HematologyBC CancerButaro Cancer Center of ExcellenceCancer Research UKChildren's Oncology Group (COG)Dan L Duncan Comprehensive Cancer Center, Baylor College of MedicineDana-Farber Brigham Cancer CenterEuropean Hematology AssociationGerman Breast Group (GBG)German Hodgkin Study GroupHOVONIRCCS Azienda Ospedaliero-Universitaria di Bologna – Policlinico Sant'OrsolaJuravinski Cancer Centre / Escarpment Cancer Research InstituteLYSA – The Lymphoma Study AssociationMemorial Sloan Kettering Cancer CenterNordic Lymphoma GroupSWOG Cancer Research NetworkUniversity Hospital Southampton / Centre for Cancer ImmunologyUniversity Hospitals Birmingham / University of Birmingham Cancer Research Centre

pathways

1
Oncogenic viruses

terms

12
ABVD, BEACOPP and BrECADD (Hodgkin lymphoma regimens)Adolescent and young adult (AYA) oncologyAutologous stem cell transplant (ASCT)Cancer during pregnancyDeauville five-point scaleDeauville score and PET-adapted therapyEpstein-Barr virus (EBV) in cancerLugano classification / Ann Arbor stagingLymphoma (tissue type)Overall survival (OS)Progression-free survival (PFS)Reed-Sternberg cell

trials

8
AETHERAAHOD2131 (COG / NCTN)CheckMate 205ECHELON-1GHSG HD21KEYNOTE-204RATHLSWOG S1826

pairings

3
Caution: bleomycin lung toxicity, especially with brentuximab or G-CSFCaution: cumulative anthracycline dose and the heartPD-1 blockade + AVD chemotherapy

ideas

14
A live stock-out map for essential chemotherapy drugsA survivorship passport app for adolescent and young adult survivorsA survivorship research endowment funded by a levy on curative therapy pricesAn Epstein-Barr virus vaccine to prevent nasopharyngeal cancer and lymphomasCash for transport and food to stop families abandoning curative treatmentCD30 CAR-T for multiply relapsed Hodgkin lymphomaChemotherapy-free Hodgkin lymphoma: brentuximab + PD-1 in early stageDefault fertility preservation referral for every patient under 40 before treatmentFertility preservation offered and funded by default before gonadotoxic treatmentGuaranteed-quality childhood cancer medicines free of charge in 50 countriesLet adolescents from age 12 into adult trials when the cancer biology is the sameNurse-led chemotherapy day units with a doctor on a screenStop over-excluding people who could become pregnant; study pregnancy exposureTailored screening for second cancers in survivors with known high-risk exposures

collections

2
Leukemia & Lymphoma Society (LLS)Lymphoma Research Foundation (LRF)

people

2
Alex F. HerreraEmil "Tom" Frei III

bottlenecks

2
Most of the world has almost no cancer careSurvivorship and late effects are neglected

key papers

2
ECHELON-1: brentuximab vedotin replacing bleomycin in first-line chemotherapy for advanced Hodgkin lymphomaSWOG S1826: nivolumab plus AVD chemotherapy versus brentuximab-AVD for advanced Hodgkin lymphoma in adolescents and adults

Key papers

2top
rctNew England Journal of Medicine 2024changed practice
SWOG S1826: nivolumab plus AVD chemotherapy versus brentuximab-AVD for advanced Hodgkin lymphoma in adolescents and adults

S1826 moved checkpoint blockade into first-line Hodgkin lymphoma and made N-AVD a preferred regimen for advanced disease in patients from adolescence to older age, while removing radiotherapy for most. It also showed the value of a single trial spanning paediatric and adult groups. Longer follow-up is needed for overall survival and late immune effects in young patients.

rctNew England Journal of Medicine 2018changed practice
ECHELON-1: brentuximab vedotin replacing bleomycin in first-line chemotherapy for advanced Hodgkin lymphoma

ECHELON-1 made a targeted antibody-drug conjugate part of first-line Hodgkin therapy and eventually showed that this saves lives, not just relapses. It set the reference arm against which nivolumab-AVD (SWOG S1826) and BrECADD (HD21) were later compared. Neuropathy is the main price and needs proactive dose modification.

Latest papers

top
Literature trend1,430 papers in the last 12 months+12% vs prior 12How this is computed
Latest papers · live from Europe PMC
Open in Europe PMC

Query for this cancer: (TITLE:"Hodgkin lymphoma" OR ABSTRACT:"Hodgkin lymphoma") AND (treatment OR therapy OR trial OR survival OR diagnosis). Results are unfiltered search hits about Hodgkin lymphoma, not a curated reading list.

Connected

93top

Pages like this

not linked directly; found by shared links

technologies

12
Antibody-drug conjugate (ADC)Autologous stem cell transplant (high-dose therapy)Cardio-oncologyctDNA monitoring in lymphoma (PhasED-seq, clonoSEQ)Cytotoxic chemotherapyFDG PETImmune checkpoint inhibitorsIMRT / IGRT (modern external beam)Mammography & tomosynthesisOncofertility and fertility preservationPET-adapted (response-adapted) therapySurvivorship care and late-effects surveillance

targets

3
CD30PD-1PD-L1

drugs

8
Not mapped hereGlycopeptide antibiotic (DNA-cleaving)
Bleomycin · Blenoxane
ApprovedADC
Brentuximab vedotin · Adcetris
ApprovedCytotoxic chemotherapy (anthracycline)
Doxorubicin · Adriamycin
ApprovedMonoclonal antibody (anti-PD-1)
Nivolumab · Opdivo / Opdivo Qvantig (SC)
ApprovedMonoclonal antibody (anti-PD-1)
Pembrolizumab · Keytruda / Keytruda Qlex (SC)
Not mapped hereAnti-PD-1 monoclonal antibody (IgG1, Fc-engineered null)
Penpulimab · Penpulimab-kcqx
Not mapped hereVinca alkaloid (microtubule inhibitor)
Vinblastine · Velban
Not mapped hereVinca alkaloid (microtubule inhibitor)
Vincristine · Oncovin / Marqibo

companies

5
Bristol Myers SquibbForesight DiagnosticsMerck & Co. (MSD)Pfizer (incl. Seagen)Takeda

institutions

19
American Society of HematologyBC CancerButaro Cancer Center of ExcellenceCancer Research UKChildren's Oncology Group (COG)Dan L Duncan Comprehensive Cancer Center, Baylor College of MedicineDana-Farber Brigham Cancer CenterEuropean Hematology AssociationGerman Breast Group (GBG)German Hodgkin Study GroupHOVONIRCCS Azienda Ospedaliero-Universitaria di Bologna – Policlinico Sant'OrsolaJuravinski Cancer Centre / Escarpment Cancer Research InstituteLYSA – The Lymphoma Study AssociationMemorial Sloan Kettering Cancer CenterNordic Lymphoma GroupSWOG Cancer Research NetworkUniversity Hospital Southampton / Centre for Cancer ImmunologyUniversity Hospitals Birmingham / University of Birmingham Cancer Research Centre

pathways

1
Oncogenic viruses

terms

12
ABVD, BEACOPP and BrECADD (Hodgkin lymphoma regimens)Adolescent and young adult (AYA) oncologyAutologous stem cell transplant (ASCT)Cancer during pregnancyDeauville five-point scaleDeauville score and PET-adapted therapyEpstein-Barr virus (EBV) in cancerLugano classification / Ann Arbor stagingLymphoma (tissue type)Overall survival (OS)Progression-free survival (PFS)Reed-Sternberg cell

trials

8
AETHERAAHOD2131 (COG / NCTN)CheckMate 205ECHELON-1GHSG HD21KEYNOTE-204RATHLSWOG S1826

pairings

3
Caution: bleomycin lung toxicity, especially with brentuximab or G-CSFCaution: cumulative anthracycline dose and the heartPD-1 blockade + AVD chemotherapy

ideas

14
A live stock-out map for essential chemotherapy drugsA survivorship passport app for adolescent and young adult survivorsA survivorship research endowment funded by a levy on curative therapy pricesAn Epstein-Barr virus vaccine to prevent nasopharyngeal cancer and lymphomasCash for transport and food to stop families abandoning curative treatmentCD30 CAR-T for multiply relapsed Hodgkin lymphomaChemotherapy-free Hodgkin lymphoma: brentuximab + PD-1 in early stageDefault fertility preservation referral for every patient under 40 before treatmentFertility preservation offered and funded by default before gonadotoxic treatmentGuaranteed-quality childhood cancer medicines free of charge in 50 countriesLet adolescents from age 12 into adult trials when the cancer biology is the sameNurse-led chemotherapy day units with a doctor on a screenStop over-excluding people who could become pregnant; study pregnancy exposureTailored screening for second cancers in survivors with known high-risk exposures

collections

2
Leukemia & Lymphoma Society (LLS)Lymphoma Research Foundation (LRF)

people

2
Alex F. HerreraEmil "Tom" Frei III

bottlenecks

2
Most of the world has almost no cancer careSurvivorship and late effects are neglected

key papers

2
ECHELON-1: brentuximab vedotin replacing bleomycin in first-line chemotherapy for advanced Hodgkin lymphomaSWOG S1826: nivolumab plus AVD chemotherapy versus brentuximab-AVD for advanced Hodgkin lymphoma in adolescents and adults